InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
0
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-31.7%
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the full record of transactions filed by Lee Michael Stewart, Director. Insider active across 2 companies, notably Fate Therapeutics INC. Aggregated, 22 disclosures have been logged. History available since 2 June 2021. The latest transaction was disclosed on 31 March 2025 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations22 total
828 shares0Common StockSEC:0001104659-25-031355:0
1,734 shares0Common StockSEC:0001104659-25-000434:0
1,734 shares0Common StockSEC:0001104659-24-105558:0
1,734 shares0Common StockSEC:0001104659-24-077492:0
1,734 shares0Common StockSEC:0001104659-24-042722:0
492 shares0Common StockSEC:0001104659-24-001045:0
492 shares0Common StockSEC:0001104659-23-106523:0
492 shares0Common StockSEC:0001104659-23-077731:0
492 shares0Common StockSEC:0001104659-23-041781:0
230 shares0Common StockSEC:0001104659-23-001105:0
230 shares0Common StockSEC:0001104659-22-106086:0
230 shares0Common StockSEC:0001104659-22-077498:0
8,650 shares0Common StockSEC:0001104659-22-070679:0
230 shares0Common StockSEC:0001104659-22-042453:0
130 shares0Common StockSEC:0001104659-22-001188
130 shares0Common StockSEC:0001104659-22-001188:0
130 shares0Common StockSEC:0001104659-21-122675:0
130 shares0Common StockSEC:0001104659-21-122675
130 shares0Common StockSEC:0001104659-21-088919:0
130 shares0Common StockSEC:0001104659-21-088919
2,681 shares0Common StockSEC:0001104659-21-077002
2,681 shares0Common StockSEC:0001104659-21-077002:0
22 of 22 declarations
About Lee Michael Stewart
Michael Stewart Lee is a Board Member at Fate Therapeutics Inc. and IGM Biosciences, Inc. He brings valuable expertise in biotechnology, helping to guide the development and innovation strategies of the companies. His role is essential in ensuring that the boards make informed decisions regarding research projects and market opportunities.
